Cargando…
Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET
PURPOSE: Measurement of heterogeneity in (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) images is reported to improve tumour phenotyping and response assessment in a number of cancers. We aimed to determine whether measurements of (18)F-FDG heterogeneity could improve differ...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644685/ https://www.ncbi.nlm.nih.gov/pubmed/28589254 http://dx.doi.org/10.1007/s00259-017-3733-1 |
_version_ | 1783271772351627264 |
---|---|
author | Cook, Gary J. R. Lovat, Eitan Siddique, Muhammad Goh, Vicky Ferner, Rosalie Warbey, Victoria S. |
author_facet | Cook, Gary J. R. Lovat, Eitan Siddique, Muhammad Goh, Vicky Ferner, Rosalie Warbey, Victoria S. |
author_sort | Cook, Gary J. R. |
collection | PubMed |
description | PURPOSE: Measurement of heterogeneity in (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) images is reported to improve tumour phenotyping and response assessment in a number of cancers. We aimed to determine whether measurements of (18)F-FDG heterogeneity could improve differentiation of benign symptomatic neurofibromas from malignant peripheral nerve sheath tumours (MPNSTs). METHODS: (18)F-FDG PET data from a cohort of 54 patients (24 female, 30 male, mean age 35.1 years) with neurofibromatosis-1 (NF1), and clinically suspected malignant transformation of neurofibromas into MPNSTs, were included. Scans were performed to a standard clinical protocol at 1.5 and 4 h post-injection. Six first-order [including three standardised uptake value (SUV) parameters], four second-order (derived from grey-level co-occurrence matrices) and four high-order (derived from neighbourhood grey-tone difference matrices) statistical features were calculated from tumour volumes of interest. Each patient had histological verification or at least 5 years clinical follow-up as the reference standard with regards to the characterisation of tumours as benign (n = 30) or malignant (n = 24). RESULTS: There was a significant difference between benign and malignant tumours for all six first-order parameters (at 1.5 and 4 h; p < 0.0001), for second-order entropy (only at 4 h) and for all high-order features (at 1.5 h and 4 h, except contrast at 4 h; p < 0.0001–0.047). Similarly, the area under the receiver operating characteristic curves was high (0.669–0.997, p < 0.05) for the same features as well as 1.5-h second-order entropy. No first-, second- or high-order feature performed better than maximum SUV (SUVmax) at differentiating benign from malignant tumours. CONCLUSIONS: (18)F-FDG uptake in MPNSTs is higher than benign symptomatic neurofibromas, as defined by SUV parameters, and more heterogeneous, as defined by first- and high-order heterogeneity parameters. However, heterogeneity analysis does not improve on SUVmax discriminative performance. |
format | Online Article Text |
id | pubmed-5644685 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-56446852017-10-18 Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET Cook, Gary J. R. Lovat, Eitan Siddique, Muhammad Goh, Vicky Ferner, Rosalie Warbey, Victoria S. Eur J Nucl Med Mol Imaging Original Article PURPOSE: Measurement of heterogeneity in (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) images is reported to improve tumour phenotyping and response assessment in a number of cancers. We aimed to determine whether measurements of (18)F-FDG heterogeneity could improve differentiation of benign symptomatic neurofibromas from malignant peripheral nerve sheath tumours (MPNSTs). METHODS: (18)F-FDG PET data from a cohort of 54 patients (24 female, 30 male, mean age 35.1 years) with neurofibromatosis-1 (NF1), and clinically suspected malignant transformation of neurofibromas into MPNSTs, were included. Scans were performed to a standard clinical protocol at 1.5 and 4 h post-injection. Six first-order [including three standardised uptake value (SUV) parameters], four second-order (derived from grey-level co-occurrence matrices) and four high-order (derived from neighbourhood grey-tone difference matrices) statistical features were calculated from tumour volumes of interest. Each patient had histological verification or at least 5 years clinical follow-up as the reference standard with regards to the characterisation of tumours as benign (n = 30) or malignant (n = 24). RESULTS: There was a significant difference between benign and malignant tumours for all six first-order parameters (at 1.5 and 4 h; p < 0.0001), for second-order entropy (only at 4 h) and for all high-order features (at 1.5 h and 4 h, except contrast at 4 h; p < 0.0001–0.047). Similarly, the area under the receiver operating characteristic curves was high (0.669–0.997, p < 0.05) for the same features as well as 1.5-h second-order entropy. No first-, second- or high-order feature performed better than maximum SUV (SUVmax) at differentiating benign from malignant tumours. CONCLUSIONS: (18)F-FDG uptake in MPNSTs is higher than benign symptomatic neurofibromas, as defined by SUV parameters, and more heterogeneous, as defined by first- and high-order heterogeneity parameters. However, heterogeneity analysis does not improve on SUVmax discriminative performance. Springer Berlin Heidelberg 2017-06-07 2017 /pmc/articles/PMC5644685/ /pubmed/28589254 http://dx.doi.org/10.1007/s00259-017-3733-1 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Cook, Gary J. R. Lovat, Eitan Siddique, Muhammad Goh, Vicky Ferner, Rosalie Warbey, Victoria S. Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET |
title | Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET |
title_full | Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET |
title_fullStr | Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET |
title_full_unstemmed | Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET |
title_short | Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET |
title_sort | characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)f-fdg pet |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644685/ https://www.ncbi.nlm.nih.gov/pubmed/28589254 http://dx.doi.org/10.1007/s00259-017-3733-1 |
work_keys_str_mv | AT cookgaryjr characterisationofmalignantperipheralnervesheathtumoursinneurofibromatosis1usingheterogeneityanalysisof18ffdgpet AT lovateitan characterisationofmalignantperipheralnervesheathtumoursinneurofibromatosis1usingheterogeneityanalysisof18ffdgpet AT siddiquemuhammad characterisationofmalignantperipheralnervesheathtumoursinneurofibromatosis1usingheterogeneityanalysisof18ffdgpet AT gohvicky characterisationofmalignantperipheralnervesheathtumoursinneurofibromatosis1usingheterogeneityanalysisof18ffdgpet AT fernerrosalie characterisationofmalignantperipheralnervesheathtumoursinneurofibromatosis1usingheterogeneityanalysisof18ffdgpet AT warbeyvictorias characterisationofmalignantperipheralnervesheathtumoursinneurofibromatosis1usingheterogeneityanalysisof18ffdgpet |